Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy - Wikidata - wikimedia - TriplyDB

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

http://www.wikidata.org/entity/Q28314934

about

Clinical applications of PD-L1 bioassays for cancer immunotherapy.Probing protein flexibility reveals a mechanism for selective promiscuity.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Immune-Mediated Therapies for Liver Cancer.A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.Clinical trials of CAR-T cells in China Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.Local and global anatomy of antibody-protein antigen recognition.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.Self-assembled DNA nanocentipedes as multivalent vehicles for enhanced delivery of CpG oligonucleotides.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms

P2860

Q33702815-5D44F1E4-64D0-4278-AC53-A9257EFBFC48 Q33732362-90AAC19E-EDA5-450C-AE94-20A04DB402BB Q33912075-F17BA133-21CD-41DE-87F7-5D0C0BB67BBF Q37686620-CFAFCBEB-107C-4D04-AED2-C1FE658B97D3 Q38621228-986FCBAA-3B78-4190-8F3C-A05D83CB7841 Q38735433-8796EC33-5C66-40C8-A124-BDF419D146C0 Q39144327-8B789A61-68AB-456F-B937-AB0DCB209D2C Q41668880-9148C98A-E2FB-4FC9-9828-78ABFFA631AE Q41704131-4A9660F8-849E-4021-937E-9FDBC06A3C15 Q41849636-86118DA0-2E5C-4590-9AA9-99B45201108C Q42323191-FD2DE9D0-BEA2-4018-94E7-9DF71C87AC41 Q42654456-6784397A-52A2-4537-85D6-FC42F1B1F842 Q47132253-F9D81BBC-A575-4601-BD92-7251E92BCF7D Q47316363-0C9A3968-0DEF-4B1D-9C95-ADCDF1217972 Q47424027-F0D9960E-E01F-4B17-8668-C1E4A0BB5A7D Q47783661-D36B4A36-D0D9-484C-B482-C367D564A262 Q47842052-460296E9-5D7F-4AD0-8D5A-421F6C6ED998 Q48043038-F255835A-BDCC-45DE-B13E-7B77791A8094 Q48165756-206B5DBC-504F-4489-A699-514CB152A299 Q48689919-03076450-0400-46BE-A2E2-C793E9AB5415 Q49219959-3585DD02-16FA-440D-A10F-F8D2A550A976 Q50887767-579F7904-6540-476D-8848-A6BF51A802BA Q52630284-128D164C-7F38-4811-B452-95E48A03CF7A Q52639397-D12E5B81-8E38-45CE-A685-3A116C20334B Q55243180-B7B98E2D-C2C0-4A9A-AE35-4F10C7D24958 Q55336684-ECCCB188-603B-4132-A518-7D4752D9BF02 Q55394825-2D8AFFFE-39B6-4DCD-9DB0-F067463F0946 Q58554222-0CD38484-36D6-42F7-81AD-D3A85803E4C6

P2860

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

http://www.wikidata.org/entity/Q28314934

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@ast

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@en

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@nl

type

label

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@ast

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@en

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@nl

prefLabel

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@ast

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@en

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@nl

P1433

Q28314934-E01952EC-4247-4185-9C9B-17D831A34E12

P1476

Q28314934-61CFCDFF-49DC-4554-884F-8ADDC1ED9710

P2093

Q28314934-007C9B2D-9FA8-4A30-A3C6-04EBAB30FDC2

Q28314934-1CBC8C3E-F3B2-4944-8558-DA303D96AF34

Q28314934-21CF1C03-90F6-4E96-988D-0D3EAB1DD935

Q28314934-3641192E-9C00-41C3-9668-609310108CF9

Q28314934-4B25DD9E-14F0-4AD5-9BB7-4D81399A6D59

Q28314934-4B9F94E7-F5ED-4DE8-A2E6-49F676120B76

Q28314934-590C133C-44D5-434E-9A1F-511E59CA16B9

Q28314934-5A5C0A8A-EA29-4743-824A-D084B87E7713

Q28314934-77378472-E5F6-4591-B5C5-C5CA03CE8525

Q28314934-9FE334CC-F94D-4E4A-840B-F25F642DD74C

P2860

Q28314934-0BAE5D03-4927-4FFA-AF88-D3AFFD818E6A

Q28314934-165FB842-5002-4F28-88CD-72987E940C4B

Q28314934-17463CEE-A2FD-4A0F-AFBD-63D1D8CCA7DC

Q28314934-1797B799-9F3B-4E75-B2C5-740C61E6D2CA

Q28314934-1989B6E6-93CD-41CC-AFCB-D7DAD915A77A

Q28314934-1D615CBA-46CA-4554-897C-C001296F0C8D

Q28314934-1D75A69A-99FC-4084-AFBC-2B9BC516E54D

Q28314934-22F08CCC-9AAA-4748-8EEC-A92F28E7FF3E

Q28314934-2EC01DF0-30D3-4277-A1E4-51357CFB9DDF

Q28314934-2F705AA1-C8DF-4F4B-A26F-D903047C3AFE

P2888

Q28314934-2FD02713-6156-429D-8CD0-543CCDC9E7FF

P304

Q28314934-774A946B-59B8-43BC-8323-B0C5CE16CBFF

P31

Q28314934-1DFEF157-6127-4964-B42A-024301E610F6

P3181

Q28314934-8CB22792-4176-4A27-97AE-F82343A649B8

P356

Q28314934-6C822973-3318-4D66-8396-29D72E22A5D0

P407

Q28314934-C409BF2B-A580-4094-937E-56A52A52203A

P478

Q28314934-B11DF398-9552-430C-B8C1-37C5096C8B28

P577

Q28314934-CB4A051F-C342-4C02-BA3F-184B036A2763

P6179

Q28314934-CDD2FC52-C950-4A70-A86B-70AEB29E94B1

P698

Q28314934-53A5AAC9-EEEA-449D-B24C-6A1589E570FC

P921

Q28314934-261EB573-3758-450D-A24C-AEEE7C2CA99C

Q28314934-68A48356-6705-47A3-AD51-20203C4D8628

P932

Q28314934-812C2510-F8ED-4772-B290-6A647C8B953B

P3181

P356

P1433

Nature Communications

P1476

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

@en

P2093

Heejin Lim

http://www.w3.org/2001/XMLSchema#string

Hyun Tae Lee

http://www.w3.org/2001/XMLSchema#string

Jaemo Choi

http://www.w3.org/2001/XMLSchema#string

Jee Un Lee

http://www.w3.org/2001/XMLSchema#string

Ji Young Son

http://www.w3.org/2001/XMLSchema#string

Jongseok Chae

http://www.w3.org/2001/XMLSchema#string

Ju Yeon Lee

http://www.w3.org/2001/XMLSchema#string

Kyeong Young Park

http://www.w3.org/2001/XMLSchema#string

Seong Eon Ryu

http://www.w3.org/2001/XMLSchema#string

Sung Hyun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 costimulation: a review

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

CD28/B7 system of T cell costimulation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Tremelimumab: research and clinical development

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Molecular mechanisms of T cell co-stimulation and co-inhibition

Structure of murine CTLA-4 and its role in modulating T cell responsiveness

P2888

P304

13354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2744427

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NCOMMS13354

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047014821

http://www.w3.org/2001/XMLSchema#string

P698

27796306

http://www.w3.org/2001/XMLSchema#string

P921

P932

5095608

http://www.w3.org/2001/XMLSchema#string